摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-ethyl-5-(1H-pyrazol-4-yl)pyrimidin-2-amine

中文名称
——
中文别名
——
英文名称
4-ethyl-5-(1H-pyrazol-4-yl)pyrimidin-2-amine
英文别名
——
4-ethyl-5-(1H-pyrazol-4-yl)pyrimidin-2-amine化学式
CAS
——
化学式
C9H11N5
mdl
——
分子量
189.22
InChiKey
VJFRKCFQFZUSID-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    80.5
  • 氢给体数:
    2
  • 氢受体数:
    4

文献信息

  • 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
    申请人:NOVARTIS AG
    公开号:US20150152093A1
    公开(公告)日:2015-06-04
    The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2a , R 2b and R 3 -R 7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
    该发明涉及一种公式(I)或其药学上可接受的盐,其中R1、R2a、R2b和R3-R7如下。该发明还涉及含有公式(I)化合物的组合物,并且涉及使用这些化合物来抑制具有新型活性的突变IDH蛋白质。该发明进一步涉及使用公式(I)化合物来治疗与这种突变IDH蛋白质相关的疾病或障碍,包括但不限于细胞增殖障碍,如癌症。
  • 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
    申请人:NOVARTIS AG
    公开号:US10112931B2
    公开(公告)日:2018-10-30
    The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
    本发明涉及式 (I): 或其药学上可接受的盐,其中 R1、R2a、R2b 和 R3-R7 在此处。本发明还涉及含有式(I)化合物的组合物,以及此类化合物在抑制具有新变态活性的突变 IDH 蛋白中的用途。本发明进一步涉及式(I)化合物在治疗与此类突变IDH蛋白相关的疾病或紊乱中的用途,包括但不限于细胞增殖紊乱,如癌症。
  • US20140275083A1
    申请人:——
    公开号:US20140275083A1
    公开(公告)日:2014-09-18
查看更多